<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">17947719</PMID>
<DateCompleted>
<Year>2007</Year>
<Month>11</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>12</Month>
<Day>01</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1527-7755</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>25</Volume>
<Issue>30</Issue>
<PubDate>
<Year>2007</Year>
<Month>Oct</Month>
<Day>20</Day>
</PubDate>
</JournalIssue>
<Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title>
<ISOAbbreviation>J. Clin. Oncol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.</ArticleTitle>
<Pagination>
<MedlinePgn>4722-9</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The prognosis for patients with recurrent glioblastoma multiforme is poor, with a median survival of 3 to 6 months. We performed a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan.</AbstractText>
<AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">This phase II trial included two cohorts of patients. The initial cohort, comprising 23 patients, received bevacizumab at 10 mg/kg plus irinotecan every 2 weeks. The dose of irinotecan was based on the patient's anticonvulsant: Patients taking enzyme-inducing antiepileptic drugs (EIAEDs) received 340 mg/m2, and patients not taking EIAEDs received 125 mg/m2. After this regimen was deemed safe and effective, the irinotecan schedule was changed to an accepted brain tumor regimen of four doses in 6 weeks, in anticipation of a phase III randomized trial of irinotecan versus irinotecan and bevacizumab. The second cohort, comprising 12 patients, received bevacizumab 15 mg/kg every 21 days and irinotecan on days 1, 8, 22, and 29. Each cycle was 6 weeks long and concluded with patient evaluations, including magnetic resonance imaging.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The 6-month progression-free survival among all 35 patients was 46% (95% CI, 32% to 66%). The 6-month overall survival was 77% (95% CI, 64% to 92%). Twenty of the 35 patients (57%; 95% CI, 39% to 74%) had at least a partial response. One patient developed a CNS hemorrhage, which occurred in his 10th cycle. Four patients developed thromboembolic complications (deep venous thrombosis and/or pulmonary emboli).</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Bevacizumab and irinotecan is an effective treatment for recurrent glioblastoma multiforme and has moderate toxicity.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Vredenburgh</LastName>
<ForeName>James J</ForeName>
<Initials>JJ</Initials>
<AffiliationInfo>
<Affiliation>Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA. vrede001@mc.duke.edu</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Desjardins</LastName>
<ForeName>Annick</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Herndon</LastName>
<ForeName>James E</ForeName>
<Initials>JE</Initials>
<Suffix>2nd</Suffix>
</Author>
<Author ValidYN="Y">
<LastName>Marcello</LastName>
<ForeName>Jennifer</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Reardon</LastName>
<ForeName>David A</ForeName>
<Initials>DA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Quinn</LastName>
<ForeName>Jennifer A</ForeName>
<Initials>JA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rich</LastName>
<ForeName>Jeremy N</ForeName>
<Initials>JN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sathornsumetee</LastName>
<ForeName>Sith</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gururangan</LastName>
<ForeName>Sridharan</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sampson</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wagner</LastName>
<ForeName>Melissa</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bailey</LastName>
<ForeName>Leighann</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bigner</LastName>
<ForeName>Darell D</ForeName>
<Initials>DD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Friedman</LastName>
<ForeName>Allan H</ForeName>
<Initials>AH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Friedman</LastName>
<ForeName>Henry S</ForeName>
<Initials>HS</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>4 R37 CA11898</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>5 P50 CA108786</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>5 P50 NS20023</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Clin Oncol</MedlineTA>
<NlmUniqueID>8309333</NlmUniqueID>
<ISSNLinking>0732-183X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>2S9ZZM9Q9V</RegistryNumber>
<NameOfSubstance UI="D000068258">Bevacizumab</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7673326042</RegistryNumber>
<NameOfSubstance UI="D000077146">Irinotecan</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>XT3Z54Z28A</RegistryNumber>
<NameOfSubstance UI="D002166">Camptothecin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>J Clin Oncol. 2007 Oct 20;25(30):4705-6</RefSource>
<PMID Version="1">17947716</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>Nat Clin Pract Oncol. 2008 Apr;5(4):186-7</RefSource>
<PMID Version="1">18285760</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>Nat Clin Pract Neurol. 2008 May;4(5):242-3</RefSource>
<PMID Version="1">18212790</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>J Clin Oncol. 2008 Feb 20;26(6):1012-3; author reply 1013</RefSource>
<PMID Version="1">18281677</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>J Clin Oncol. 2008 Nov 10;26(32):5304-5; author reply 5305</RefSource>
<PMID Version="1">18854564</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000911">Antibodies, Monoclonal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000068258">Bevacizumab</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002166">Camptothecin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005909">Glioblastoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000077146">Irinotecan</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009364">Neoplasm Recurrence, Local</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009367">Neoplasm Staging</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015996">Survival Rate</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2007</Year>
<Month>10</Month>
<Day>20</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2007</Year>
<Month>11</Month>
<Day>14</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2007</Year>
<Month>10</Month>
<Day>20</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">17947719</ArticleId>
<ArticleId IdType="pii">25/30/4722</ArticleId>
<ArticleId IdType="doi">10.1200/JCO.2007.12.2440</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>